Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : South Africa's Tutu gets jab to help start inoculation drive

05/17/2021 | 11:40am EDT

JOHANNESBURG (AP) — South Africa's anti-apartheid icon Archbishop Desmond Tutu, 89, came out of retirement Monday to help the country launch its drive to inoculate older citizens against the coronavirus.

“All my life I have tried to do the right thing and, today, getting vaccinated against COVID-19 is definitely the right thing to do,” said Tutu, the former Anglican archbishop of Cape Town who won the Nobel Prize Prize in 1984 for his peaceful work to end apartheid, South Africa's previous regime of racist rule by the country's white minority.

Tutu was rolled in a wheelchair into a vaccination center in Cape Town where he and his wife, Leah, were among those getting shots.

“It was wonderful to get out of the house and meet these dedicated healthcare workers who gave us our vaccines," said Tutu in a statement. “To all of you on the frontlines who have been working to keep us safe for more than a year now, I salute you.”

South Africa has said it intends to inoculate nearly 5 million citizens aged 60 and above by the end of June.

Shots of the Pfizer vaccine were given to South Africans in a few nursing homes and to a few thousand people aged 60 and older on Monday to start the campaign.

The health department said it plans to give shots to more than 7,700 senior citizens at 102 nursing homes by the end of the week, with a total 50,000 in those facilities to get their first jabs by the end of May.

So far the country has inoculated just over 478,000 of its health care workers with Johnson & Johnson vaccines and it plans to give the shots to the remainder of its 1.2 million health workers by the end of this week.

According to the latest online registrations, more than 1.2 million citizens 60 and older and 945,000 health workers have completed online registrations to get vaccinated.

South Africa now has nearly 1 million doses of the Pfizer vaccine, after receiving a delivery of 325,260 doses of the vaccine on Sunday night.

“The Pfizer vaccines are safe and work well, even against the variant that is dominant in this country,” Health Minister Zweli Mkhize said Sunday night in a speech that was broadcast nationally.

By the end of June, the country expects to have received 4.5 million Pfizer doses and 2 million of the Johnson & Johnson vaccine, Mkhize said.

South Africa's vaccination drive comes as the country is seeing a rise in cases of COVID-19 and experts warn of a resurgence as the country approaches the colder months of the Southern Hemisphere’s winter.

South Africa’s 7-day rolling average of daily new cases has nearly doubled over the past two weeks from 2.07 new cases per 100,000 people on May 2 to 4.13 new cases per 100,000 people on May 16. The country’s death rate has also nearly doubled over the past two weeks from 0.06 deaths per 100,000 people on May 2 to 0.11 deaths per 100,000 people on May 16.

South Africa has been the country hardest hit by the pandemic in Africa with more than 1.6 million confirmed infections and more than 55,000 reported deaths.

South Africa’s rollout of the vaccine has faced serious delays, including the return of 1 million AstraZeneca doses that were found to provide only minimal protection against the COVID-19 variant dominant in the country.

It also temporarily halted giving the Johnson & Johnson vaccines to health care workers after the U.S. Food and Drug Administration flagged rare blood clots in some patients who had received the vaccine.

Mkhize has warned that those who have been vaccinated should continue to practice standard prevention measures like wearing masks and social distancing.

“The vaccine will protect you from getting severe COVID disease or dying from COVID. However, no vaccine works 100% and we also still do not know whether vaccination prevents transmission of the virus," Mkhize said. “It is therefore still important to follow the standard COVID-19 safety precautions to protect yourself and those around you.”

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.15% 163.84 Delayed Quote.2.92%
PFIZER, INC. 1.57% 39.42 Delayed Quote.5.43%
All news about JOHNSON & JOHNSON
10:43aJOHNSON & JOHNSONá : How Johnson & Johnson Helped Us Adopt 11 Children
AQ
06/19MODERNAá : U.S. administers more than 317 mln doses of COVID-19 vaccines - CDC
RE
06/18The Week Ahead -- Barron's
DJ
06/17JOHNSON & JOHNSONá : Eying border reopening, Mexico begins J&J vaccine rollout i..
AQ
06/17Canada Vaccine Panel Recommends Against AstraZeneca PLC for Second Dose
DJ
06/17US to Spend $3.2 Billion on COVID Treatments Research
MT
06/16ASTRAZENECAá : Second Phase of Covid-19 Vaccinations Begins
AQ
06/16EU Says Johnson & Johnson May Not Meet Vaccine Supply Commitment After Jabs C..
MT
06/15US, EU Vow to Provide COVID-19 Vaccine to Two-Thirds of World's Population by..
MT
06/15JOHNSON & JOHNSONá : Aspen to Dispatch 300 000 J&J Vaccines for Teachers
AQ
More news
Financials (USD)
Sales 2021 92 812 M - -
Net income 2021 22 227 M - -
Net Debt 2021 314 M - -
P/E ratio 2021 19,5x
Yield 2021 2,58%
Capitalization 427 B 427 B -
EV / Sales 2021 4,60x
EV / Sales 2022 4,30x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 183,67 $
Last Close Price 161,98 $
Spread / Highest target 25,9%
Spread / Average Target 13,4%
Spread / Lowest Target -2,46%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795
ELI LILLY AND COMPANY29.44%198 668